Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;13(7):847-55; quiz 856.
doi: 10.6004/jnccn.2015.0102.

Head and Neck Cancers, Version 1.2015

David G Pfister  1 , Sharon Spencer  1 , David M Brizel  1 , Barbara Burtness  1 , Paul M Busse  1 , Jimmy J Caudell  1 , Anthony J Cmelak  1 , A Dimitrios Colevas  1 , Frank Dunphy  1 , David W Eisele  1 , Robert L Foote  1 , Jill Gilbert  1 , Maura L Gillison  1 , Robert I Haddad  1 , Bruce H Haughey  1 , Wesley L Hicks Jr  1 , Ying J Hitchcock  1 , Antonio Jimeno  1 , Merrill S Kies  1 , William M Lydiatt  1 , Ellie Maghami  1 , Thomas McCaffrey  1 , Loren K Mell  1 , Bharat B Mittal  1 , Harlan A Pinto  1 , John A Ridge  1 , Cristina P Rodriguez  1 , Sandeep Samant  1 , Jatin P Shah  1 , Randal S Weber  1 , Gregory T Wolf  1 , Frank Worden  1 , Sue S Yom  1 , Nicole McMillian  1 , Miranda Hughes  1
Affiliations

Head and Neck Cancers, Version 1.2015

David G Pfister et al. J Natl Compr Canc Netw. 2015 Jul.

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

PubMed Disclaimer

References

    1. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer—part 1: epidemiology, presentation, and prevention. BMJ. 2010;341:c4684. - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–4301. - PMC - PubMed
    1. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175–201. - PMC - PubMed
    1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550–4559. - PMC - PubMed
    1. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34–54. - PubMed

MeSH terms